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Abstract
Waist-to-hip ratio (WHR) is a prominent cardiometabolic risk factor that increases cardio-met-
abolic disease risk independently of BMI and for which multiple genetic loci have been identi-
fied. However, WHR is a relatively crude proxy for fat distribution and it does not capture all
variation in fat distribution. We here present a study of the role of coding genetic variants on
fat mass in 6 distinct regions of the body, based on dual-energy X-ray absorptiometry imaging
on more than 17k participants. We find that the missense variant CCDC92S70C, previously
associated with WHR, is associated specifically increased leg fat mass and reduced visceral
but not subcutaneous central fat. The minor allele-carrying transcript of CCDC92 is constitu-
tively more highly expressed in adipose tissue samples. In addition, we identify two coding
variants in SPATA20 and UQCC1 that are associated with arm fat mass. SPATA20K422R is a
low-frequency variant with a large effect on arm fat only, and UQCC1R51Q is a common vari-
ant reaching significance for arm but showing similar trends in other subcutaneous fat depots.
Our findings support the notion that different fat compartments are regulated by distinct
genetic factors.
Introduction
While generalised adiposity, as measured by body mass index (BMI), is a well-established and
major risk factor for cardio-metabolic diseases, body fat distribution is increasingly being rec-
ognised as an even stronger determinant of metabolic risk[1, 2]. For example, Yusuf et al.[1]
showed that waist-to-hip ratio (WHR) is a stronger predict of myocardial infarction than BMI.
To date, the overwhelming majority of genome and exome-wide association studies on fat
distribution have focussed on waist and hip circumference and WHR[3, 4]. While these mea-
sures are easy and cheap to obtain on a large scale, they do not capture all variation in fat
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distribution. For example, WHR does not capture peripheral fat stored in the upper limbs and
the distribution of overall central fat over the subcutaneous and visceral compartments, of
which the latter have been suggested to have discordant effects on cardio-metabolic risk[5–8].
Furthermore, circumference-based estimates of fat accumulation do not take into account dif-
ferences in lean mass and bone structure and mass. Therefore, genetic association studies
based on direct measures of regional fat mass may help unpick mechanisms underlying the
expansion of distinct fat depots.
Quantification of fat mass in distinct regions of the body requires imaging methods with
post-image processing to derive delineation of tissues, such as magnetic resonance imaging or
dual x-ray absorptiometry (DXA). DEXA-based measures of regional body fat have been
shown to correlate more strongly with metabolic risk factors than traditional anthropometric
risk factors, such as BMI and waist and hip circumference[9]. We therefore investigated associ-
ations of common and rare non-synonymous variants covered on the exome chip with 6 dis-
tinct fat compartments, derived from DXA scans on 17,212 participants from 3 cohorts. We
hypothesise that by identifying fat depot-specific genetic loci we may gain better insight into
the site-specific role of adipose tissue on disease aetiology.
Results and discussion
We tested the associations of all non-synonymous genetic variants covered on the Illumina
Human Exome Bead chip with DXA-derived fat mass in the 6 body fat regions: arm fat, leg fat,
gynoid fat, total android fat, visceral abdominal fat and subcutaneous abdominal fat (S1
Table). The regional fat phenotypes were adjusted for the first 4 genetic principal components,
age and % body fat and the residuals were rank-based inverse normally transformed for men
and women separately. The exome chip meta-analyses included up to 17,212 participants of
European ancestry from the Oxford Biobank[10], Fenland[11] and EPIC-Norfolk[12] cohorts
(Table 1 and S1 Table). Three non-synonymous variants reached exome-wide significance
(p<2×10−7) (Fig 1, Table 2 and S2 Table): rs11057401, a common missense variant in Coiled-
Coil Domain Containing 92 (CCDC92S70C); rs62621401, a novel low-frequency missense vari-
ant in Spermatogenesis Associated 20 (SPATA20K422R) and rs4911494, a common missense
variant in Ubiquinol-Cytochrome C Reductase Complex Assembly Factor 1 (UQCC1R51Q).
Heterogeneity tests based on Cochran’s Q statistics indicate no significant differences among
the effect estimates in the 6 contributing datasets (p for Cochran’s Q statistic for rs11057401 =
0.19, for rs4911494 = 0.61 and rs62621401 = 0.42). The three loci identified here show the
same direction of effect in both men and women. However, the effect size of rs11057401
(CCDC92) on visceral fat was two-fold stronger in men than in women whereas the association
with lower body fat mass showed no difference between the sexes. An additional 30 non-syn-
onymous variants reached suggestive significance across 38 tests (p<10−6, S3 Table), including
Table 1. Study cohorts.
Study name Sample size (% men) Genotyping array QC Passed Variants. Total Na Polymorphic variants. N
Fenland-ExomeChip 1,145 (45.8%) Illumina Exome BeadChip v1.0 240,859 95,739
Fenland-CoreExome 997 (45.2%) Illumina Infinium Core Exome 24 v1 array 234,179 85,218
Fenland-Axiom 7,363 (47.5%) Affymetrix UK Biobank Axiom array 58,240 57,864
EPIC-Norfolk 3,101 (45.0%) Affymetrix UK Biobank Axiom array 56,837 52,020
Oxford Biobank Exome Chip 3,281 (43.7%) Illumina Exome BeadChip v1.0 245,138 125,912
Oxford Biobank Axiom 1,325 (41.4%) Affymetrix UK Biobank Axiom array 62,732 56,820
a Counts represent the number of variants in each dataset that overlap with the Illumina Exome Beadchip v1.0 content after standard QC metrics are applied.
https://doi.org/10.1371/journal.pone.0217644.t001
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a large haplotype block on chromosome 17 containing 8 missense variants across the SPPL2C,
MAPT, KANSL1 genes and GDF5S276A in LD with UQCC1R51Q.
The rs11057401 CCDC92S70C variant (EAF = 0.32) is predicted to cause a deleterious amino
acid change as assessed by predictSNP[13]. The minor allele of rs11057401 shows significant
opposing effects on android, specifically visceral fat mass, and lower body fat, in the sex-com-
bined additive model (total abdominal fat mass: β = -0.065, SE = 0.012, p = 3.5×10−8; visceral
abdominal fat mass: β = -0.063, SE = 0.012, p = 1.3×10−7; leg fat mass: β = 0.075, SE = 0.020,
p = 4.9×10−10) (Table 2). These data extend WHR associations reported by Justice, et al.[3] and
Lotta et al.[11] at this locus. Lotta et al.[11] describe the contribution of leg fat mass; we here
demonstrate an additional opposing effect specifically on abdominal visceral fat mass but not
for abdominal subcutaneous fat mass, which would correspond to the already observed associ-
ation with increased waist circumference but with the present analysis showing that the effect
is confined to the intra-abdominal fat depot only. Found on chromosome 12q24, CCDC92 is
ubiquitously expressed with highest levels in adipose tissue, brain and testes. It is a nuclear
Fig 1. The effect size and direction of effect of meta-analysis findings. Effect size and direction of effect of the three
exome-wide significant missense variants: A. rs11057401 in CCDC92 (EAF = 0.32), B. rs62621401 in SPATA20
(EAF = 0.016) and C. rs4911494 in UQCC1 (EAF = 0.62). Data is presented for the 6 DXA measures under
investigation and is presented as the beta value ± SD. The meta-analysis significance level using an additive model for
gender combined (All) as well as for gender stratified analysis, together with the N indicated to the right of the data in
parentheses. DXA measures are Arm fat mass (Arm), Total android fat mass (Android), Subcutaneous android fat
mass (Abdominal subcut), Visceral android fat mass (Abdominal visceral), Gluteal fat mass (Gynoid) and Leg fat mass
(Leg). Exome-wide significant data (p<2E-7) are in bold and underlined.
https://doi.org/10.1371/journal.pone.0217644.g001
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protein interacting with the centriole-ciliary interface[11] and may also be involved in DNA
repair[14]. The lead variant tags a large haplotype of at least 99 SNPs (r2>0.9) across a number
of genes including the putative transcription factor Zinc Finger Protein 664 (ZNF664) and
Dynein Axonemal Heavy chain 10 (DNAH10) (Table 2). There is also strong evidence for mul-
tiple eQTL signals across this haplotype which includes three genes, i.e. CCDC92, DNAH10
and ZNF664[15]. Previous GWAS studies have also associated SNPs in this haplotype with a
reduction in insulin resistance[11], improvements in metabolic syndrome[16], reduced
WHRadjBMI[3, 4], increased adiponectin levels[17] and with increased plasma HDL-choles-
terol and reduced triglyceride concentrations[18–20]. Ablation of CCDC92 and DNAH10 in
mouse OP9-K cells impairs adipogenesis and reduced lipid accumulation[11]. To further
define the likely causative gene or genes in this complex region we undertook a number of
gene expression studies in human regional adipocytes and whole adipose tissue. CCDC92 and
ZNF664 showed very similar expression profiles between abdominal subcutaneous adipose tis-
sue(ASAT), gluteal subcutaneous adipose tissue(GSAT) and arm subcutaneous adipose tissue
derived (ARM) cDNA (Figs 2 and 3, S1–S3 Figs), whilst DNAH10 expression could not be
detected in cDNA from either of the diverse human adipose tissues or cultured primary
human preadipocytes, making it an unlikely effector transcript. Across a panel of 52 paired
ASAT and GSAT cDNA samples (S1 Fig), qPCR showed small differences in expression of
CCDC92 and ZNF664 between ASAT and GSAT as well as between lean and obese individuals.
In a cultured human primary pre-adipocyte differentiation time course experiment, both
CCDC92 and ZNF664 showed a significant upregulation by day 4 of differentiation (Fig 2A
and 2B) but no difference in expression levels was observed between preadipocytes of ASAT
and GSAT origin. Whilst this study focusses on exonic coding variants, recent studies have
highlighted that coding variants are not always the causal variant at the locus, but may be asso-
ciated with the trait simply because they are correlated with the causal (non-coding) variant
[21]. To that end, we also sought to investigate the reported eQTL signals at this locus, for both
CCDC92 and ZNF664 (GTEx project[15] and[11]) using allele-specific qPCR; a method that
allows us to assess expressed allelic imbalance in heterozygous individuals and thus an eQTL.
This showed a highly statistically significant increased expression of transcripts found on the
minor allele haplotype for both genes (ASAT 5.8%, GSAT 4.9%, Fig 3A and 3B). Of functional
Table 2. Primary exome-wide significant findings.
rsID Chr:Position
(GRCH37)
Gene Amino
acid
Change
Ref
Allele
Alt
Allele
DXA
derived
Fat Depot
N Alternate
Allele
Frequency
Effect
Size
standard
error
Pvaluea Haplotype region
(GRCH37)b
Number of
SNPs in LD
with index
SNPc
rs11057401 12:124427306 CCDC92 S70C T A Total
Android
Fat
17184 0.321 -0.065 0.012 3.5E-08 chr12:124403769–
124495203
99
Visceral
Fat
16967 0.321 -0.063 0.012 1.3E-07
Leg Fat 17184 0.321 0.075 0.012 4.9E-10
rs62621401 17:48628160 SPATA20 K422R A G Arm Fat 17204 0.016 -0.293 0.043 1.5E-11 chr17:48623825–
48633043
7
rs4911494 20:33971914 UQCC1 R51Q C T Arm Fat 17197 0.616 -0.063 0.012 1.3E-07 chr20:33887955–
34194423
129
a Exome-wide significance was set to 2×10−7
b The haplotype region is defined as the furthest 3’ and 5’ SNPs with a R2 >0.9 with the index SNP
c SNP count is based on 1000 genome SNP data with SNPs in high LD (R2>0.9) with the index SNP
https://doi.org/10.1371/journal.pone.0217644.t002
Regional fat depot masses and protein-coding gene variants
PLOS ONE | https://doi.org/10.1371/journal.pone.0217644 May 30, 2019 4 / 17
importance is that this allelic expression imbalance would result in the increased expression of
the predicted deleterious serine-70-cysteine amino acid substitution in the CCDC92 protein.
Interestingly, zinc finger proteins such as ZNF664 have been suggested to regulate the expres-
sion of near-by genes[16]. The observed co-regulatory expression pattern of ZNF664 and
CCDC92 could then possibly be due to the eQTL acting on ZNF664 which then upregulates
the CCDC92 transcript carrying the deleterious coding variant. Further work needs to be done
to investigate this.
The rs62621401 SPATA20K422R is a rare variant (EAF 0.016), which has to our knowledge
not been reported for any other phenotypes. This amino acid substitution is predicted to be
Fig 2. Expression of candidate genes across a human primary adipocyte differentiation time course. cDNA
expression of CCDC92 (A), ZNF664 (B), SPATA20 (C), UQCC1 (D) and GDF5 (E) was measured over a 14-day
adipogenic differentiation time-course using primary preadipocytes from abdominal subcutaneous adipose tissue
(ASAT) and gluteal subcutaneous adipose tissue (GSAT) fat depots[40]. Data are shown as DDCt values (normalized
to PPIA and PGK1; n = 6, mean ± SEM). A multivariate general linear model was used to test for statistical significance
between depots and time, and to assess depot x time interactions. p-values are presented in the shaded boxes, NS: non-
significant.
https://doi.org/10.1371/journal.pone.0217644.g002
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Fig 3. eQTL assessment of exome-wide significant loci by allele-specific qPCR expression. Allelic expression was measured on 4 candidate transcripts in our
three exome-wide significant regions using allele-specific qPCR. Data is presented as the % of the minor allele detected compared to the major allele, as
described in the methods, with a line indicating the mean and 95%CIs. To assess the rs11057401 eQTL haplotype the proxy SNP rs9863 was assessed for
Regional fat depot masses and protein-coding gene variants
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benign and allele-specific qPCR on paired ASAT and GSAT cDNA samples of five Oxford Bio-
bank participants heterozygous for rs62621401 did not reveal any association with expression
of SPATA20 (Fig 3C). This variant shows a large effect size and is the first locus to be associated
with arm fat mass (β = -0.29, SE = 0.04, p = 1.5×10−11, Table 2 and Fig 1B) with an estimated
per-allele effect size in the Oxford Biobank (n = 4,606) of 125g less arm fat mass (-5.8%, 95%
confidence interval (CI) = [-9.3%,-2.3%]) in men and 67g (-2.6%, 95% CI = [-5.3%,0.4%]) in
women (approximate fat mass (grams) per allele after adjusting for covariates with % change
in parentheses, S1 Table). SPATA20, linked to spermatogenesis in mice[22], is highly expressed
in human testes but also ubiquitously expressed, including in adipose tissue. SPATA20 is a
putative member of the thioredoxin family and other members of this family have been shown
to be involved in preadipocyte proliferation[23] and pro-adipogenic Wnt signalling[24].
SPATA20 expression was higher in men than women, although this was only significant for
GSAT (p = 0.01) (S1 Fig). Expression of SPATA20 during adipocyte differentiation showed an
increase between days 0 to 7 of adipogenesis then a drop back to pre-differentiation levels
between days 7 and 14 (p = 8.3×10−8, Fig 2C) suggesting a role for this gene in adipocyte devel-
opment. Surprisingly, despite the arm-specific association, expression of SPATA20 was similar
between arm fat, ASAT and GSAT (Panel A in S2 Fig). However, qPCR assessment of a num-
ber of developmental genes (Homeobox genes) in arm adipose tissue compared to ASAT and
GSAT showed significant differences (Panel B in S2 Fig), which suggests that arm fat is devel-
opmentally distinct from the other fat depots assessed. It is therefore possible that SPATA20 is
involved in an arm fat-specific developmental pathway.
The rs4911494 UQCC1R51Q (EAF = 0.62) variant was also inversely associated with arm fat
mass (Table 2 and Fig 1C) but was not predicted as damaging by predictSNP. Whilst exome-
wide significance is only observed for arm fat, the arm fat-lowering allele is suggestively associ-
ated with less fat in all peripheral and subcutaneous fat depots and in both men and women
(Fig 1C and S1 Table). UQCC1 plays a role in mitochondrial respiratory chain complex III pro-
tein expression[25] and is structurally similar to the mouse Bfzb controlling mouse brown fat
[26]. Previous associations at this locus, either the arm fat reducing allele of rs4911494 reported
here or SNPs in LD have shown; reduced height [27], reduced body weight[28], increased
WHRadjBMI[3] and increased osteoarthritis risk [29]. Another missense variant in the nearby
canonical Wnt signalling gene GDF5 (rs224331) is in LD with rs4911494 (r2>0.9) and reaches
suggestive significance with arm fat mass in women (β = 0.13, SE = 0.03, p = 8.97×10−7, S3
Table). During adipogenesis, expression of UQCC1 increases (p = 2.4×10−22, Fig 2D) but with
no difference between ASAT and GSAT in cultured pre-adipocytes. Allele-specific qPCR
showed that the minor allele (rs4911494) was associated with a small but statistically significant
decrease in expression of UQCC1 in ASAT (per-allele percentage change in expression =
-1.25%, p = 8.7×10−4; Fig 3D). It is unclear whether this small change is biologically relevant.
GDF5 expression was not detected in adipose tissue cDNA samples. However, during adipo-
genesis GDF5 showed transient expression at day 2, highlighting the possibility that GDF5 is a
regulator of early adipocyte differentiation.
CCDC92 (A) and the transcribed region proxy SNP rs1054852 for ZNF664 (B). The index SNP rs62621401 was used to assess the SPATA20 transcript (C) and
the index SNP rs4911494 for UQCC1. Paired samples were compared between abdominal subcutaneous adipose tissue (ASAT) and gluteal subcutaneous
adipose tissue (GSAT) and genomic DNA (gDNA). For each transcript ABI Taqman genotyping assays were selected that fall within the transcribed sequence.
gDNA selected from the same individuals as the cDNAs acts as a paired control with presumed equal allele expression. Deviation from 50% for gDNA,
particularly pronounced in SPATA20 (C), represents inherent imbalance in assay technical performance and position of optimal Ct between Vic and Fam
fluorescence. By using paired gDNAs to select cDNAs allelic expression imbalance can be resolved by comparing cDNA to its paired gDNA. Significance was
assessed with paired t-test in SPSSv24. Mean differences between comparisons and statistical significance is presented in shaded boxes. NS: Non-significant.
The single outlier seen for SPATA20 (C) was replicated in a second cDNA synthesis and both ASAT and GSAT. No phenotype differences were observed for
this individual and no obvious genetic differences were observed.
https://doi.org/10.1371/journal.pone.0217644.g003
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Conclusion
This study represents the largest exome chip meta-analysis on DXA-derived discrete fat depot
masses to date. The value of better-defined fat depot regions is illustrated at the CCDC92 locus.
The CCDC92S70C variant shows a clear effect on visceral fat mass, but not on subcutaneous
abdominal fat mass, while an opposing effect on lower body fat mass was observed. These find-
ings refine our understanding of the role of the CCDC92 locus on distinct fat compartments
compared to what could be derived from genetic analyses on circumference-based measures of
fat distribution. Whether the opposing effects on visceral versus leg fat mass are because
genetic variation at the CCDC92 locus plays a direct role in both depots, or because the oppo-
site effect on one depot is simply a consequence of a primary effect on the other depot is
unclear and will require further investigation. A previous study investigating computerised
tomography (CT) scan-derived visceral and subcutaneous fat mass also found associations at
the CCDC92 locus with ZNF664 (rs1048497) and DNAH10 (rs1316952)[30] but these SNPs
are both in low LD with the index variant in this study (r2 0.34 and 0.18, respectively) and may
represent independent signals. No other previously reported loci associated with CT-derived
visceral fat measures[30] were replicated to suggestive significance. The limitation of using an
algorithm-based approximation of visceral fat mass, as presented here with the DXA platform
should be acknowledged in comparison with the direct measurements provided by CT or MRI
methods. However, DXA-derived estimation of visceral fat mass is very strongly correlated
with CT-derived measures (r2 = 0.96)[31] as has associations with T2D and CVD risk profiles
comparable with CT and MRI methods[9]. These data and the depth of previous GWAS find-
ings at the CCDC92-ZNF664 locus highlight this as an important region in regulating adipose
tissue distribution. In addition, we report two coding variants associated with arm fat mass: a
novel low-frequency variant in SPATA20 with a large effect size that seems to only affect arm
fat mass and a common variant in UQCC1 that has additional but weaker effects on other sub-
cutaneous fat depots. Overall, when comparing these data to exome chip analyses on standard
anthropometric traits, such as WHR[3], we replicate few of the reported loci, likely due to the
relatively small sample size of our analyses. However, we have identified a locus, not found
for any traditional anthropometric traits, for arm fat mass and refined the tissue-specific asso-
ciation for another locus (CCDC92), highlighting the value of more defined regional fat
measures.
Regional fat depots have distinct physiological regulation with an impact on the whole body
metabolic homeostasis, with distinct transcriptomes demonstrating functional differences and
differences in origin[7]. This study further supports genetic evidence for overall, distinct regu-
lation of regional fat depots.
Materials and methods
Population cohorts
Oxford biobank. The Oxford Biobank (OBB) cohort (http://www.oxfordbiobank.org.uk)
consists of an age-stratified random sample of men and women (aged 30 to 50 years) of Euro-
pean ancestry resident in Oxfordshire, UK, as described previously[10]. All participants gave
written, informed consent to participate, and studies were approved by the Oxfordshire
Research Ethics Committee (08/H0606/107+5). A total of 3,281 individuals from the Oxford
Biobank had both measures of fat mass with GE Lunar iDXA[9] and Illumina Human Exome
Beadchip genotypes after QC checks. An additional 1,325 individuals contained DXA data and
Affymetrix UK Biobank Axiom array genotype data from which overlapping ExomeChip data
was extracted for the purposes of this study (Table 1).
Regional fat depot masses and protein-coding gene variants
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Fenland. The Fenland study is a longitudinal cohort consisting of 12,435 participants
born between 1950 and 1975. Participants were recruited from the general population through
GP surgeries in Cambridge, Ely and Wisbech (Cambridgeshire, East Anglia)[32] and under-
went detailed metabolic phenotyping and genome-wide genotyping. Ethical approval for the
study was was given by the Cambridge Local Ethics committee (ref. 04/Q0108/19) and all par-
ticipants gave their written consent prior to entering the study.
A total of 1,145 individuals from the Fenland cohort had both measures of fatmass with GE
Lunar iDXA[9] and Illumina Human Exome BeadChip genotypes after QC checks (Fenland-
ExomeChip, Table 1), a further 997 had Illumina Infinium Core Exome data and 7,363 had
Affymetrix UK Biobank Axiom array genotype data from which overlapping ExomeChip data
was extracted for the purpose of this study (Table 1).
EPIC-Norfolk. EPIC-Norfolk is one of the two UK-based centres of the European Pro-
spective Investigation into Cancer and nutrition (EPIC) study–an ongoing multi-centre Euro-
pean cohort study set up to study the role of nutrition in cancer risk [33] The EPIC-Norfolk
study is a cohort of 25,000 participants, aged 45–74 at baseline, who were recruited through
GP surgeries in Norfolk (East Anglia, UK) from the general population between 1993 and
1997[12]. The study was approved by the Norfolk Research Ethics Committee (ref. 05/Q0101/
191) and all participants gave their written consent before entering the study. A total of 3,101
individuals had Affymetrix UK Biobank Axiom array genotype data from which overlapping
ExomeChip data was extracted for the purposes of this study (Table 1).
DXA-derived depot-specific fat mass measures
For all cohorts depot-specific fat mass was quantified using GE Lunar iDXA (GE Healthcare,
Bucks, UK). As previously described[9] these give high precision estimates of body composi-
tion. The standard setting of the Encore software (version 14.0; GE Healthcare, Bucks, UK)
was used to automatically define regions of interest ensuring that boundaries were consistent
between cohorts. The descriptives for the DXA measures used are presented in S1 Table. Vis-
ceral fat mass and android subcutaneous fat mass were not measured directly. Visceral fat
mass was calculated using an algorithm within the Encore software as described elsewhere[9,
31] and the android subcutaneous fat mass was calculated by subtracting the visceral fatmass
from total android fat mass. The DXA scanning was calibrated as per manufacturer’s instruc-
tions. For arm and leg fat masses the combined masses of the left and right limbs were used, as
calculated in the software.
Exome-wide genotype analysis
Datasets. Six data sets from three cohorts, Oxford Biobank[10], Fenland[34] and EPIC--
Norfolk[12] (Table 1), equalling a total of 17,212 individuals of European ancestry were com-
piled for this analysis. The Illumina Exome BeadChip v1.0 genotype content was used as the
base content. Where other genotype arrays were used (see Table 1) only the content overlap-
ping with the Illumina ExomeChip were selected. The breakdown of descriptives for each of
the 6 datasets can be found in S1 Table. Standardized, between cohorts, Exome-Chip protocols
and quality control (QC) metrics were employed for genotype calling for each cohort sepa-
rately using zCall [35] and individuals and loci that failed QC removed before association anal-
ysis. Allele calls, chromosome positions and strand were harmonised between cohorts with a
common reference files using PLINK and converted to .vcf files in plinkseq. A standard proto-
col was also shared between cohorts for harmonised phenotype transformations.
single-variant analysis. Principal component analysis was performed within each study
on LD-pruned genotype data with MAF>5% obtained using GWAS arrays. Models were
Regional fat depot masses and protein-coding gene variants
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adjusted for the first 4 genetic principal components (PCs) in order to adjust for population
stratification and relatedness, which is commonly done in exome and genome-wide associa-
tion studies[36]. All DXA-derived phenotypes were log-transformed, adjusted for the first 4
PCs, age and percentage total fat mass (calculated as the percentage of total fat mass (grams) to
total mass (grams)) and the residuals inverse normal transformed in the R statistical environ-
ment to remove systematic differences between studies/DXA instruments/operators. Percent-
age total fat mass adjusted for age and PC1-4 was also included in the analysis to assess collider
bias. Individual datasets were analysed separately in sex-combined and sex-specific analyses
using RAREMETALWORKER[37] (http://genome.sph.umich.edu/wiki/
RAREMETALWORKER). To account for cryptic relatedness, kinship matrices were first cal-
culated and added into the analysis. Single-variant analysis was performed with, additive,
recessive and dominant models.
Meta-analysis. Meta-analysis was carried out centrally using RAREMETAL[38]. Variants
were excluded if they had a call rate<90%, Hardy-Weinberg equilibrium p<10−7 and markers
on Y chromosome or mitochondrial genome. Exome-wide significance for the single-variant
analysis was set, based on the full ExomeChip content, as p<2×10−7. A suggestive significance
was set to p<10−6.
For this analysis we focussed on non-synonymous variants only, therefore all non-coding
variants and synonymous variants were filtered out post meta-analysis together with loci that
had a total heterozygous count of less than 10. The exome-wide significant findings are pre-
sented in Fig 1 and S1 Table; the additional suggestive significant findings are presented in S3
Table.
Additional informatics
For the three exome-wide significant loci the amino-acid substitutions was assessed for func-
tional significance using the predictSNP online consensus tool[13] (https://loschmidt.chemi.
muni.cz/predictsnp1/). This allows for assessment across a number of different tools to gener-
ate a consensus assessment. For CCDC92 the S70C missense variant was assessed; for UQCC1
the R51Q was assessed and for SPATA20 three different proteins as products of different splice
variants were assessed (K422R, K406R and K362R).
Adipose tissue gene expression panels
Six genes found within the three index SNP LD boundaries (Table 2) were assessed for expres-
sion levels across a collection of human adipose tissue gene expression panels. Applied Biosys-
tems Taqman assay-on-demand qPCR assays were selected for each gene that also avoid the
index SNPs presented here, for CCDC92 (ABI assay, hs01556139), ZNF664 (ABI assay,
hs00921074), DNAH10 (ABI assay, hs1387352), SPATA20 (ABI assay, hs00256188), UQCC1
(ABI assay hs00921074) and GDF5 (ABI assay, hs00167060).
For tissue panels, subcutaneous adipose tissue biopsies were collected by needle biopsy as
previously described[39]. For cell-cultured human primary preadipocytes, of both abdominal
subcutaneous adipose tissue (ASAT) and gluteal subcutaneous adipose tissue (GSAT) origin, a
differentiation time course (n = 6) was performed as described in Todorčević, et al.[40]. All
biopsies and cells were homogenized in Tri-reagent (cat. no. T9424, Sigma-Aldrich, UK) and
RNA was extracted with a standard Tri-reagent protocol. A total of 500ng RNA was used for
cDNA synthesis following standard protocols and random hexamer primers using the cDNA
Reverse Transcription Kit (Life Technologies, UK). Real-time PCR reactions were performed
on a 1/40 cDNA dilution using Taqman Assays-on-Demand (Applied Biosystems) and Kapa
Probe Fast Mastermix (Kapa Biosystems) in triplicate in a 6μl final volume and run on an
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Applied Biosystems 7900HT machine. Expression was assessed within each panel using a rela-
tive qPCR approach[41] and normalised using the previously assessed stably expressed endog-
enous control genes[39]. For the Lean/Obese Oxford Biobank panel (S1 Fig) the geometric
mean of PPIA, PGK1, PSMB6 and IPO8 were used. IPO8 was not used in a paired arm, ASAT
and GSAT panel (S2 Fig) as it was not stably expressed between arm and the other depots.
PPIA and PGK1 were used as endogenous controls for primary cell culture experiments.
Neither DNAH10 nor GDF5 could be detected above background in whole tissue cDNA
panels. GDF5 was however detected in a 14-day in vitro adipocyte differentiation time course.
Data for a panel of 52 paired ASAT and GSAT biopsy samples was used to assess expression
between sexes, between ASAT and GSAT fat depots, and between lean and obese individuals.
Descriptives for this panel are presented in S1 Fig. As both SPATA20 rs62621401 and UQCC1
rs4911494 were associated with arm fat mass their expression, along with CCDC92 and
ZNF664 was assessed in a paired arm, ASAT and GSAT cDNA panel. As there is no published
data on arm subcutaneous adipose tissue transcriptomics the additional HOX gene transcripts
HOXA5, HOXB8, HOXC8, HOXC9 and HOXC11 were assessed as these are known to be dif-
ferentially expressed between ASAT, GSAT and visceral fat (Data comparing arm subcutane-
ous adipose tissue(ARM), ASAT and GSAT gene expression are presented in S2 Fig).
The setup of a human primary adipocyte differentiation time course is described elsewhere
[40]. Relative qPCR was run as above on the adipocyte panel for CCDC92, ZNF664, SPATA20,
UQCC1 and GDF5. Data is presented in Fig 2.
Allele-specific qPCR
Both the CCDC92 and the UQCC1 loci are associated with multiple eQTL signals. Whilst we
only consider non-synonymous variants in this analysis this does not discount that the coding
locus is also under the influence of an eQTL. To assess the available data from resources such
as the GTEx portal and to assess any eQTL effect between ASAT and GSAT fat depots we used
the combined resources available within the Oxford Biobank.
Allele specific qPCR was run essentially as described in Fogarty et al.[42].
Taqman genotyping assays (Applied Biosystems) were selected to fall within the transcripts
under investigation. For CCDC92 the index SNP assay performed poorly so the Proxy SNP
rs9863 (ABI assay, C_206415_30) was selected. To assess the nearby gene ZNF664 a SNP in
high LD with the CCDC92 index SNP that fell within the ZNF664 transcript, rs1054852 (ABI
assay, C_1169873_10), was selected. For SPATA20 the index SNP was used (rs62621401, ABI
assay C_25983779_10) as was for UQCC1 (rs4911494, ABI assay, C_25472999_10). As was pre-
viously stated neither DNAH10, nor GDF5 could be detected in whole adipose tissue panels.
Therefore, allele specific qPCR could not be assessed for these two genes.
From a panel of 200 paired ASAT and GSAT cDNA samples available from the Oxford Bio-
bank, heterozygous individuals were selected. For CCDC92 and ZNF664 28 paired ASAT and
GSAT samples were selected, for UQCC1 there were 34 and for SPATA20 there were 5. Geno-
mic DNA (gDNA) for these individuals were also retrieved and diluted to 1.5ng/μl. The gDNA
is used as the control comparison to the cDNA samples as there is an equal quantity of both
alleles in heterozygous gDNA samples. By comparing the ratio of the Ct values from each allele
(the ratio of the genotype assay Vic or Fam fluorophore signals) between cDNA and gDNA
any allelic expression differences observed in the cDNA samples can be resolved. This is partic-
ularly relevant as technical variation exists with each genotyping assay; particularly pro-
nounced in SPATA20 (Fig 3C).
Data are presented as the percentage of the minor allele Ct value compared to the major
allele Ct. This is calculated by first generating a standard curve and regression statistic for each
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assay. A standard curve is generated from genomic DNA for individuals homozygous for the
major allele (BB) and minor allele (bb). Genomic DNAs are diluted to 1.5ng/μl then BB and bb
homozygotes are combined to ratios 80:20, 60:40, 50:50,40:60,80:20. Following qPCR analysis
using the dual-labelled TaqMan Genotyping assays the ratio of the B to b Ct values are calcu-
lated (Ct B minus Ct b) then plotted against the percentage of the minor allele in the dilution
series. The linear regression statistic from this standard curve is then used to calculate the per-
centage minor allele expression of the unknown heterozygous individuals. The standard curves
are presented in S3 Fig panels A-D and allele-specific qPCR data for heterozygous individuals
are presented in Fig 3.
For CCDC92, ZNF664 and UQCC1 there were sufficient cDNAs in the 200 panel, however
for SPATA20 there were only 5 individuals. Therefore, to improve the accuracy of the
SPATA20 analysis, each sample was run in triplicate 4x across the assay plate and the average
of all 4 sets of triplicates calculated. A single outlier in the SPATA20 data was followed up in a
second cDNA synthesis and persisted in both ASAT and GSAT samples. No phenotype differ-
ences were observed for this individual and no obvious genetic differences were found.
Statistical analysis
Statistical significance was assessed for each experiment in SPSS v24. For estimates of per-allele
grams fat mass change, log phenotype data was analysed in a general linear model and adjusted
for age, PC1-4 and total %fat mass then estimated marginal means were calculated (S1 Table).
Supporting information
S1 Fig. mRNA expression of candidate genes across a lean/obese adipose tissue gene
expression panel. mRNA expression of the genes CCDC92, ZNF664, UQCC1 and SPATA20
across a panel of paired abdominal subcutaneous adipose tissue (ASAT) and gluteal subcuta-
neous adipose tissue (GSAT) cDNA samples from the Oxford Biobank. The panel consisted of
25 male and 29 female healthy individuals selected for either high or low BMI (Lean male,
n = 13, age 44.5±0.9 yrs, BMI 22.7±0.3 kg/m2, fasting blood glucose 5.2±0.1 mmol/l; Obese
males, n = 12, age 43.4±1.2 yrs, BMI 34.9±5.2 kg/m2, fasting blood glucose 5.6±0.1 mmol/l;
Lean females, n = 15, age 44±1.0 yrs, BMI 21.2±0.2 kg/m2, fasting blood glucose 4.8±0.1
mmol/l; Obese Females, n = 14, age 44±1.0 yrs, BMI 33.6±0.6 kg/m2, fasting blood glucose 5.2
±0.1 mmol/l–data expressed as mean ±SEM). Data are shown as the mean ± SEM DDCt values
(normalized to the geometric mean of the endogenous control genes PPIA, PGK1, IPO8 and
PSMB6) as described previously[39, 41]. A multivariate general linear model was used to test
for statistical significance between gender, fat depots and obesity and to assess interactions. P-
values are presented in the shaded box, NS: non-significant.
There were small but significant differences in expression of CCDC92, ZNF664 and UQCC1
between fat depots in lean individuals but this difference was lost and expression was signifi-
cantly reduced, in obese individuals. This is in keeping with a general quiescent state observed
in transcripts associated with adipocyte metabolic activity in obesity.
(TIF)
S2 Fig. mRNA expression of candidate genes and homeobox genes across a panel of 22
paired arm, abdominal subcutaneous adipose tissue (ASAT) and gluteal subcutaneous adi-
pose tissue (GSAT). mRNA expression of the candidate genes A: CCDC92, ZNF664, UQCC1
and SPATA20 and a selection of developmental HOX genes B: HOXA5, HOXB8, HOXC8,
HOXC9 and HOXC11 were determined by real-time qPCR. Data are shown as the mean
±SEM DDCt values (normalized to PPIA, PGK1 and PSMB6; n = 22). A univariate general
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linear model was used to test for statistical significance between depots. P-values for the HOX
genes in B are presented in the shaded box.
(TIF)
S3 Fig. Allele specific qPCR standard curves and CCDC92-ZNF664 regression analysis. The
standard curve and regression statistic used to calculate the percentage minor allele expression
with allele-specific qPCR is shown above for CCDC92 (A), ZNF664 (B), SPATA20 (C) and
UQCC1 (D). To quantify any allelic expression imbalance for the four genes a standard curve
was generated from genomic DNA for individuals homozygous for the Major allele (BB) and
Minor allele (bb). Genomic DNAs are diluted to 1.5ng/μl then BB and bb homozygotes were
combined to ratios 80:20, 60:40, 50:50,40:60,80:20 to generate a standard curve. Following
qPCR analysis using dual labelled TaqMan Genotyping assays the ratio of the B to b allele Ct
values are calculated (Ct B minus Ct b) then plotted against the percentage of the minor allele
in the dilution series. The linear regression statistic from this (A, B, C and D above) is then
used to calculate the percentage minor allele expression of our unknown individuals. For
CCDC92 (A), ZNF664 (B) and UQCC1 (D) three different pairs of homozygote individuals
were used to generate each standard curve and a Mean ± SEM plotted for each dilution (A, B
and D). For SPATA20 only one genomic DNA homozygote minor allele individual was avail-
able so an error bar cannot be displayed.
As discussed in the main text there was an observed co-regulatory pattern of expression
between CCDC92 and ZNF664 across different cDNA panels. To assess any correlation
between these two genes within the samples, the allele-specific qPCR paired data points were
plotted and regression statistic calculated (Graphs E and F). For both abdominal subcutaneous
adipose tissue (ASAT) (E) and gluteal subcutaneous adipose tissue (GSAT) (F) there was a sig-
nificant correlation, further supporting the co-regulatory pattern of expression.
(TIF)
S1 Table. Population cohort descriptives.
(DOCX)
S2 Table. Exome-wide significant loci. Detailed data on the three exome-wide significant loci
described. DXA parameters are included for all measures and meta-analysis statistics for the
additive model. DXA measures are arm fatmass (Arm), Total android fat mass (Android), Sub-
cutaneous android fat mass (Subcut), Visceral android fat mass (Visceral), Gluteal fat mass
(Gluteal) and Leg fat mass (Leg). Effect size data for suggestive exome-wide significance (p< =
10−6) is shown in bold. Exome-wide significant data (p<2E-7) are in bold and underlined.
a The impact of missense variants were assessed using the PREDICTsnp online consensus tool
[13] (https://loschmidt.chemi.muni.cz/predictsnp1/).
b Approximate fat mass (grams) changes per allele is shown where test reaches suggestive sig-
nificance and were calculated as marginal means after adjusting for age, PCs1-4 and %fatmass
as covariates in a general linear model, implemented in SPSS v24
(DOCX)
S3 Table. Exome-wide loci showing suggestive level of statistical significance. Additional
non-synonymous loci where statistical tests did not reach exome-wide significance but did
reach a suggestive significance cut off of p< = 10–6 are included above.
a Where it reaches suggestive significance the model is shown as Additive (add), Recessive(rec)
or Dominant (Dom).
b The impact of missense variants were assessed using the predictSNP online consensus tool
[13] (https://loschmidt.chemi.muni.cz/predictsnp1/).
c The cluster of 8 Missense SNPs found at the SPPL2C-MAPT-KANSL1 locus on chromosome
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17 are part of a single haplotype that extends across ~400kb in this region containing >2300
SNPs (r2>0.9), rather than independent signals.
(DOCX)
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